Loading stock data…
NERV
$6.07-0.40 (-6.18%)
Market ClosedLast close May 1
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Minerva Neurosciences, Inc. in the Healthcare sector is trading at $6.07. The stock is currently 51% below its 52-week high of $12.46, remaining 45.6% above its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why NERV maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.07
Potential Upside
5%
Whystock Fair Value$6.37
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$318.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
208.47%
Volume
Today's trading volume
108,200
Recent News
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of schizophrenia—an area where management has historically lagged behind treatments for positive sympto
Minerva Neurosciences: Q4 Earnings Snapshot
BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Wednesday reported a loss of $283.7 million in its fourth quarter.
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most
Key Insights Minerva Neurosciences' significant individual investors ownership suggests that the key decisions are...
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia
Minerva Neurosciences (NASDAQ:NERV) hosted a virtual key opinion leader (KOL) event focused on its development candidate roluperidone for negative symptoms in schizophrenia, outlining the clinical rationale for targeting negative symptoms, the challenges of measuring them in trials, and an update on
Minerva Neurosciences: Q3 Earnings Snapshot
BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Wednesday reported a loss of $2.7 million in its third quarter.